Published in the Proceedings of the National Academy of Sciences lately.

Predicated on their knowledge, clinicians at the Salzburg clinic report that the Agility MLC’s new design provides them with an increase of precise dose sculpting features and remarkably lower nontherapeutic radiation dose sent to the patient. ‘Looking closely at several prostate cancer cases, we’ve calculated a measurable improvement in dosage shaping accuracy with Agility’s high-quality, five millimeter leaves,’ says Felix Sedlmayer, M.D., Professor and Chairman, Department of Radio-Oncology and Radiotherapy, SALK and Paracelsus Medical University.Ferrara, M.D., D.Sc., and Sophie Paczesny, M.D., Ph.D.: ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Web host Disease and Death Although mortality related to graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation has been decreased,1,2 acute GVHD remains a major complication of allogeneic transplantation, occurring in two the transplant recipients around.3,4 High-dosage systemic glucocorticoids stay the first-series therapy for GVHD,5-9 although just fifty % of patients have complete resolution of GVHD by time 28 after therapy initiation.6 Patients who do not have a reply to GVHD therapy are at high risk for death without relapse of the primary disease for which the transplantation was performed within 6 months after therapy initiation.17 However, none of the studies were designed to identify biomarkers of glucocorticoid level of resistance.